Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Functional programming replaces mutable state and side effects with predictable, composable functions. By embracing ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, recently sold a significant chunk of his company's common stock. The CEO of Recursion Pharmaceuticals recently disposed of 120 ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Tree recursion is a technique used to traverse a tree-like data structure by recursively visiting each node and its children. It’s widely used in computer science, particularly in algorithms that ...

function exp() { let left = addExp(); readToken("+"); let right = addExp(); return left + right; } function addExp() { return oneOf( parenExp, inline(() => readToken ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...